Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of California, Los Angeles | OTHER |
| Huntington Hospital | OTHER_GOV |
| Hoag Memorial Hospital Presbyterian | OTHER |
| Columbia University |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this research study is to determine whether the investigational drug GM602, is effective and safe in the treatment of ischemic stroke (strokes caused by a blood clot blocking the flow of blood through one, or more of the blood vessels supplying the brain) when administered up to 18 hours after symptoms begin.
Stroke is a serious and life threatening disease. About 85% of all strokes are ischemic, caused by a blood clot or plaque that blocks a blood vessel in the brain. The thrombolytic drug tissue plasminogen activator (tPA) is the only early treatment for acute ischemic stroke approved by the FDA. Treatment with tPA must be administered within three hours of the stroke onset. Furthermore, tPA treatment carries a recognized risk of bleeding in the brain. GM602 is an investigational drug that may act as a neuroprotectant in patients who have had a stroke. It is thought to stop cell death and reduce inflammation in the injured area of the brain. This study is designed to evaluate the safety and efficacy of GM602 administered intravenously to patients in three consecutive daily doses of 320 mg/dose or 480 mg/dose, the initial dose administered within 18 hours after onset of acute ischemic stroke in the Middle Cerebral artery region.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| GM602 | Experimental | First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 12 moderate and 12 severe patients will receive GM602. |
|
| Placebo Comparator | Placebo Comparator | First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio; then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 6 moderate and 6 severe patients receive Placebo. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| GM602 | Drug | First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 12 moderate and 12 severe patients will receive GM602. |
| Measure | Description | Time Frame |
|---|---|---|
| Functional Outcome as measured by the difference in percent change in NIHSS from baseline to 90 days in patients treated with GM602 within 18 hours compared to treated with placebo as primary efficacy endpoint | NIH Stroke Scale is a standardized neurological examination intended to describe the neurological deficits found in large groups of stroke patients participating in treatment trials. Percent change from baseline in NIHSS is calculated and compared. | Day 90 |
| Measure | Description | Time Frame |
|---|---|---|
| Functional Outcome as measured by the difference in percent change in NIHSS from baseline to 30 days in patients treated with GM602 compared to treated with placebo | Percent change in NIHSS from baseline to 30 days in patients treated with any active dose of GM602 compared with placebo | Day 30 |
| Percent change in Barthel Index (BI) from baseline to 90 days in patients treated with GM602 compared to treated with placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Primary Safety Endpoints | Adverse events, Fatal intracranial hemorrhage (ICH). nonfatal symptomatic parenchymal hemorrhage, or other symptomatic ICH, Neurological deterioration during hospitalization, Number of seizures after stroke, Respiratory compromise as observed by respiratory rate | througyh 3 months |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Arbi G Ohanian, MD | Huntington Memorial Hospital | Principal Investigator |
| Sidney Starkman, MD | UCLA Stroke Center | Principal Investigator |
| Jeff Saver, MD | UCLA Stroke Center | Principal Investigator |
| David Brown, MD | Hoag Memorial Hospital Presbyterian | Principal Investigator |
| Stephan A Mayer, M.D. | Columbia University | Principal Investigator |
| Nobl Barazangi, M.D. | California Pacific Medical Center Research Institute | Principal Investigator |
| Thomas G Devlin, M.D. | University Erlanger Hospital | Principal Investigator |
| Mauricio Concha, M.D. | Sarasota Memorial Hospital | Principal Investigator |
| Anand Vaishnav, M.D. | University of Louisville | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UCLA Stroke Center (Departments of Emergency Medicine and Neurology at the University of California, Los Angeles Medical Center) | Los Angeles | California | 90095 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| OTHER |
| California Pacific Medical Center Research Institute | OTHER |
| University Hospital Erlangen | OTHER |
| Sarasota Memorial Hospital | OTHER |
| University of Louisville | OTHER |
Not provided
Not provided
Not provided
Not provided
|
|
| Placebo Comparator | Drug | First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or Matching Placebo (Bacteriostatic Saline) for GM602 in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 6 moderate and 6 severe patients will receive placebo. |
|
|
The Barthel Index is measured using both historical and direct observational information. It measures self-care and mobility and will help define the degree of residual disability. Percent change from baseline in BI is calculated. |
| Day 90 |
| Percent change in Barthel Index (BI) from baseline to 30 days in patients treated with GM602 compared to treated with placebo | Percent change in BI from baseline to 30 days in patients treated with any active dose of GM602 compared with placebo | Day 30 |
| Proportion of patients treated with any active dose of GM602 compared with placebo at each mRS level at 90 days | compared with placebo at each modified Rankin Scale (mRS) level at 90 days. | Day 90 |
| Proportion of patients treated with any active dose of GM602 compared with placebo at each mRS level at 30 days | compared with placebo at each modified Rankin Scale (mRS) level at 30 days. | Day 30 |
| Secondary safety endpoint as measured by all cause mortality data through 3 months for patients treated with GM602 compared with placebo | all cause mortality data through 3 months | Day 90 |
| Hoag Memorial Hospital Presbyterian | Newport Beach | California | 92658 | United States |
| Huntington Memorial Hospital Stroke Center | Pasadena | California | 91105 | United States |
| California Pacific Medical Center Research Institute | San Francisco | California | 94107 | United States |
| Sarasota Memorial Hospital | Sarasota | Florida | 34239 | United States |
| University of Louisville | Louisville | Kentucky | 40202 | United States |
| Columbia University Medical Center | New York | New York | 10032 | United States |
| University Erlanger Hospital | Chattanooga | Tennessee | 37403 | United States |
| ID | Term |
|---|---|
| D020521 | Stroke |
| ID | Term |
|---|---|
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided